ValenzaBio nabs $70m Series A
ValenzaBio Inc, a developer of monoclonal antibody therapeutics for autoimmune and inflammatory indications, has closed $70 million in Series A financing.
ValenzaBio Inc, a developer of monoclonal antibody therapeutics for autoimmune and inflammatory indications, has closed $70 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination